Cancer Letter Inc.
Washington, DC Doing business as The Cancer Letter Paul Goldberg
- UEI
- H3SMDHHKCTT3
- CAGE
- 35BP3
- Primary NAICS
- 513120 Periodical Publishers
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 3821 Woodley Rd NW, Washington, DC 20016, USA
- Website
- cancerletter.com
- Founded
- 1974
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Information Technology
- Software & Services
- Internet Software & Services
- Internet
- SIC code
- 89 Services, Not Elsewhere Classified
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $50,000 |
| FY2025 | $50,000 |
| FY2024 | $50,000 |
| FY2023 | $50,000 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $50,000 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Naaccr | Springfield, IL | 813920 Professional Organizations |
| Midi | — | 541511 Custom Computer Programming Services |
| National Cancer Center, National Research And Development Agency | Chuo City, Tokyo | 622310 Specialty (except Psychiatric and Substance Abuse) Hospitals |
| Erin Resch | — | 541990 All Other Professional, Scientific, and Technical Services |
| Aacr | Philadelphia, PA | 813920 Professional Organizations |
About the company
Cancer Letter Inc., doing business as The Cancer Letter, operates as a for-profit publisher and institutional subscription provider to the National Cancer Institute, competing as a prime contractor on full-and-open purchase orders with no set-asides. Based in Washington, DC, the company publishes a weekly online periodical covering cancer research, drug development, and health policy, distributed primarily through institutional subscriptions to federal research agencies classified under NAICS 513120 (Periodical Publishers).
The company's federal customer base is singular: 12 of 15 recent awards (93% by count, 86% by combined potential value of $894 thousand) come from the National Cancer Institute, with two additional awards from the National Institutes of Health. This extreme concentration reflects the company's core mission as a specialized cancer research publisher serving a focused customer. The most recent and largest transaction is a five-year institutional subscription purchase order awarded by NCI on June 16, 2026, valued at $250 thousand and extending through May 31, 2031, following a prior three-year subscription agreement awarded March 21, 2022, with a $300 thousand ceiling and options running through March 20, 2027. Both procurements used simplified acquisition procedures under FAR Part 13 without competition or set-asides. A single award (combined potential value $300 thousand) faces completion within the next twenty-four months, representing modest recompete exposure.
Cancer Letter Inc. operates exclusively as a prime contractor (100% of recent awards) with no recorded subcontract footprint. The company's total recent award count is 15, spanning from 2001 through June 2026, with infrequent activity outside the 2022–2026 window — one award in 2018, one in 2019, and one in 2021, reflecting episodic multi-year subscription renewals rather than continuous task-order activity. Combined obligated dollars across all federal awards total $723 thousand against a combined potential value of $1 million.
Quick answers
Is Cancer Letter Inc. registered in SAM.gov?
Yes. Cancer Letter Inc.'s SAM.gov registration is active through January 13, 2027.
What is Cancer Letter Inc.'s CAGE code?
Cancer Letter Inc.'s CAGE code is 35BP3, and its Unique Entity ID (UEI) is H3SMDHHKCTT3.
How much has Cancer Letter Inc. received in federal contracts?
Federal contracts obligated $50,000 to Cancer Letter Inc. in fiscal year 2025 and $200,000 in fiscal years 2023 through 2027.
How does Cancer Letter Inc. rank among federal contractors?
Cancer Letter Inc. ranked #80 in NAICS 519130 in FY2025.
What is Cancer Letter Inc.'s most recent federal award?
Cancer Letter Inc.'s most recent federal contract award is Institutional subscription to the cancer letter - permits access to the cancer letter to all NCI staff (75N98026P00782), from Office of Logisitics and Acquisition Operations (NIH), on June 16, 2026.
On GovTribe
See Cancer Letter Inc.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors